If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
253
results.
Updated on
07/05/2026 [07:05:00]
Results 125 to 150 of 253
Absstract of: US2025345278A1
Nanoparticles suitable for delivery of a linear DNA molecule are provided. Nanoparticles suitable for delivery of mRNA or DNA are provided. Further provided are uses of the nanoparticles including the use of the nanoparticles for treating disease and the use of the nanoparticles in vaccines.
Absstract of: US20260116844A1
The present invention relates to: ionized lipids comprising lipids with a branched structure; a lipid nanoparticle formulation using same; and use thereof. The ionized lipids of the present invention are a biodegradable lipid material with a lipid structure in which a heteroamine structure is branched, and the lipid nanoparticles using the ionized lipids can deliver a nucleic acid drug and the like with high efficiency, and thus can be effectively used in related technical fields such as mRNA vaccines and therapeutic agents.
Absstract of: US20260115139A1
Provided are lipids and nanoparticles containing such lipids and a cargo molecule, such as nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for making the lipids. The lipids may have the structure of Formula A as defined herein.
Absstract of: US20260115317A1
The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and/or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.
Absstract of: US20260115314A1
The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.
Absstract of: US20260115319A1
0000 Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful supplementing liver enzyme deficiencies.
Absstract of: US20260115315A1
0000 This invention relates to a drug delivery vehicle for penetrating the Blood-Brain Barrier (BBB). Said drug delivery vehicle is a cube-structured nanostructure formed from a double-stranded deoxyribonucleic acid (DNA) framework, specifically D-form DNA. This drug delivery vehicle forms a protein corona on its surface within the serum, and through this, it passes the BBB via receptor-mediated transcytosis. The present invention provides a drug delivery vehicle for the purpose of being loaded with drugs, such as antisense oligonucleotides (ASOs), to deliver them to brain tissue for the treatment of brain tumors like glioblastoma.
Absstract of: WO2026085848A1
A nano-drug delivery system modified with a phenolic acid or dipeptide for increasing the oral absorbability and bioavailability, which system is prepared from a nanocarrier and an auxiliary material. The nanocarrier is modified with a phenolic acid or dipeptide on the surface thereof as a ligand, and actively targets a receptor on the surface of intestinal epithelial cells, wherein the phenolic acid ligand is a hydroxycinnamic acid derivative, and the dipeptide ligand is a combination of a cationic amino acid and a neutral amino acid. An oral nano-drug delivery system is constructed by using a phenolic acid or dipeptide, which is an essential nutrient for a human body, as a ligand to mimic the absorption pathway of phenolic acid or dipeptide, which system significantly enhances the oral absorption efficiency of a drug by using the natural highly-efficient absorption capacity of the small intestine for nutrients.
Absstract of: US20260117071A1
Problem To provide: an ICG lipid derivative that can form a lipid-based particle that has an excellent stability and/or can selectively release a drug; and a lipid-based particle containing this ICG lipid derivative.SolutionA lipid-based particle comprising a compound represented by formula (A) below or a pharmaceutically acceptable salt thereof,wherein, R1 and R2 each independently represent —(CH2)k—CONH—R3; R3 represents a group selected from the group consisting of —(CH2)m—OPO3−—CH2—CH(CH2OCOR4)(OCOR5), branched-chain C14 to C40 alkyl, and branched-chain C14 to C40 alkenyl;R4 and R5 each independently represent straight-chain or branched-chain C13 to C21 alkyl or straight-chain or branched-chain C13 to C21 alkenyl;k represents an integer from 2 to 4; andm represents an integer from 2 to 4.
Absstract of: US20260115316A1
The present invention provides lipid nanoparticles for delivering nucleic acid to spleen tissue that can improve the efficiency of nucleic acid delivery to spleen tissue cells, and a method for delivering nucleic acid to spleen tissue by using same. A lipid nanoparticle for use in delivering a nucleic acid to a spleen tissue, including (A) an ionic lipid represented by the formula (1),(B) an anionic phospholipid or a compound represented by the formula (2),(C) cholesterol, and(D) a dimyristoylglycerol PEG represented by the formula:(definitions of symbols in the formula are as described in the specification), and a method for delivering a nucleic acid to a spleen tissue by using same.
Absstract of: US20260115162A1
Composition or association of compounds comprising: a) the active principle docosahexaenoic acid DHA (C22:6 ω-3 C22H32O2 MW 328.488) mixed with all or in part, with: b) hyaluronic acid HA4 tetrasaccharide (C28H44N2O23 MW 776) in nanoparticles c) β-caryophyllene βCP (C15H24 MW 204.35), d) furanoeudesma-1,3-diene FE (C15H18O MW 214.30), e) β-boswellic acid PBA (C30H48O3 MW 456.7). preferably for use in the treatment of nervous diseases in particular neurodegenerative diseases, method for the preparation of such composition or association of compounds and uses thereof.
Absstract of: US20260115299A1
The present invention relates to calsequestrin-based metal ion reactive particles and their applications. More specifically, the invention concerns calsequestrin-based metal ion reactive particles, which are prepared by combining bioactive substances frequently used in pharmaceuticals and cosmetics with calsequestrin (CSQ) and then reacting them with metal ions. This invention also relates to the use of these particles as drug delivery carriers, pharmaceutical compositions, or vaccines. The metal ion reactive particles according to the present invention can enhance the in vivo and in vitro stability of bioactive substances, prolong their active duration, increase their half-life in the body, and improve antigen delivery efficiency.
Absstract of: WO2026089243A1
The present invention relates to a novel ionizable sterol derivative and a lipid nanoparticle composition comprising same, in which a novel ionizable lipid synthesized on the basis of a sterol structure may simultaneously exhibit the roles of cholesterol components of ionizable lipids and structural lipids of existing lipid nanoparticles, and thus lipid nanoparticles composed thereof may be utilized as a more stable and effective drug delivery platform.
Absstract of: WO2026018264A1
The present invention relates to a nanoformulation comprising L-leucyl-L-leucine methyl ester (LLOMe) and a polymer for wound healing, which promotes multiple molecular signaling pathways essential for faster wound healing. The nanoformulation offers faster and improved wound and tissue healing, axon regeneration, antiviral immunity, stem cell proliferation, embryonic development, and anti-aging effects.
Absstract of: WO2025027089A1
The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.
Absstract of: EP4480943A1
The present invention concerns a lipid of formula (I), a composition comprising said lipid of formula (I), a process for manufacturing said lipid of formula (I) and/or said composition, the lipid of formula (I) and/or the composition for its use as a medicament, the use of said lipid of formula (I) and/or of said composition as a vector for delivering an active ingredient to subject(s), organ(s), cell(s) and/or tissue(s). a method for transfecting cells with a nucleic acid and/or a protein and/or a peptide and/or a polysaccharide and/or a lipid and/or a small organic or inorganic molecule and/or any type of bioactive molecule using said lipid of formula (I) and/or said composition, transfected cells obtained by said method, and a kit comprising said lipid of formula (I) and/or said composition.
Absstract of: WO2024263721A1
The present disclosure relates to compositions comprising nucleic acid delivery vehicles encoding the estrogen receptor beta (ERβ), and methods of treating and/or preventing diseases or disorders with ERβ dysregulated function.
Absstract of: WO2024263919A2
Described herein is a delivery system and method that can be used to deliver therapeutic compositions to epithelial cells. Provided are lipid nanoparticles comprising an ionizable lipid, a sterol, a phospholipid, and a lipid conjugated to PEG. Also described are novel molecules that can be used for gene editing. Methods include methods for delivering a therapeutic cargo to the airway or epithelium of a subject and/or a method for treating an airway or gastrointestinal disorder in a subject, the method comprising administering: i) a first lipid nanoparticle comprising a surfactant; and ii) a second lipid nanoparticle comprising a therapeutic cargo. Further methods describe a method for delivering a therapeutic cargo to the airway or epithelium of a subject and/or a method for treating an airway or gastrointestinal disorder in a subject, the method comprising administering: a lipid nanoparticle comprising a therapeutic cargo, wherein the lipid nanoparticle comprises a surfactant.
Absstract of: EP4732832A1
0001 A biocompatible composite material for controlled release is disclosed, comprising a biocompatible metal oxide structure with a loaded network of pores. The pore network of the biocompatible composite material is filled with a uniformly distributed biologically active micellizing amphiphilic molecule, the size of these pores ranging from about 0.5 to about 100 nanometers. The material is characterized in that when exposed to phosphate-buffered saline (PBS), the controlled release of the active amphiphilic molecule is predominantly diffusion-driven over time.
Absstract of: WO2024263770A1
The present disclosure relates to lipidoid compounds comprising toll-like receptor (TLR) agonists, lipid nanoparticles (LNPs) comprising the same, and methods of use thereof. In certain embodiments, the LNPs described herein are useful for enhancing the therapeutic and/or prophylactic effect of vaccine compositions.
Absstract of: WO2024259531A1
There is provided a lipid nanoparticle comprising (a) from about 40 to 100 mol % of an ionizable lipid; (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the ionizable lipid is at least one compound of formula (I): or a pharmaceutically acceptable salt thereof. The lipid nanoparticle can comprise a cargo and can be used for delivering a cargo to a cell.
Absstract of: US2024424017A1
0000 A method of inducing expression of aquaporin-4 by providing a bioconjugate having a quantum dot bound to human erythropoietin and contacting human astrocytes with the bioconjugate, which induces expression of aquaporin-4. A composition having a bioconjugate having a quantum dot bound to human erythropoietin. A method of providing a quantum dot and forming a bioconjugate by depositing human erythropoietin onto the surface of the quantum dot.
Absstract of: WO2024259530A1
A fluid composition having reduced susceptibility to at least one of oxidative spoilage and of microbial spoilage is provided, wherein the fluid composition consists of nanobubbles of gas, and each nanobubble in the fluid composition ranges in size from 1 nanometer to 500 nanometers to reduce the at least one of the oxidative spoilage and of the microbial spoilage. There is also provided a process for reducing a fluid composition susceptibility to at least one of oxidative spoilage and of microbial spoilage which consists of mixing nanobubbles of gas into the fluid composition, and each nanobubble in the fluid composition ranges in size from 1 nanometer to 500 nanometers for reducing the at least one of the oxidative spoilage and of the microbial spoilage.
Absstract of: WO2024263729A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Nº publicación: CN121927041A 28/04/2026
Applicant:
中国科学技术大学
Absstract of: CN121927041A
本申请提供了亨尼帕病毒mRNA疫苗及其制备方法与应用，属于生物医药技术领域。本申请提供的mRNA疫苗包含全长亨德拉病毒的附着糖蛋白的mRNA和mRNA疫苗递送系统，通过血清学分析以及尼帕病毒‑马来西亚毒株和亨德拉病毒攻毒保护实验，验证了本申请的疫苗只需免疫两剂即可产生很好的免疫保护效果，所述mRNA疫苗针对尼帕病毒‑马来西亚毒株和亨德拉病毒同时具有有效性，能够保护受试者免受尼帕病毒‑马来西亚毒株和亨德拉病毒的致死性感染，广谱性良好。
BOPI
Electronic site
